CFT7455 (223), an innovative molecular glue developed by C4 Therapeutics, targets IKZF1 and IKZF3 and is currently undergoing clinical trials for the treatment of MM and non-Hodgkin’s lymphoma (NHL) (Table 4). This evidence concerns the gene IKZF1 and non-Hodgkin lymphoma.